Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer
June 10th 2015Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.
Read More